Is Meloxicam Standard First-Line Treatment for Acute Gout?
Meloxicam is a standard first-line NSAID option for acute gout, but it is not specifically prioritized over other NSAIDs, as all NSAIDs demonstrate equivalent efficacy for treating acute gout flares.
Evidence-Based Recommendations
NSAIDs as First-Line Therapy
All NSAIDs, including meloxicam, are strongly recommended as first-line treatment options for acute gout alongside colchicine and corticosteroids 1.
The 2020 American College of Rheumatology and 2017 American College of Physicians guidelines both provide strong recommendations (high-quality evidence) that clinicians choose NSAIDs, corticosteroids, or colchicine to treat acute gout 2, 1.
No specific NSAID is superior to another - moderate-quality evidence demonstrates no difference between different types of NSAIDs, including indomethacin, naproxen, ibuprofen, and meloxicam 1.
Meloxicam-Specific Evidence
Meloxicam performs comparably to other NSAIDs in treating acute gout, though some data suggest it may be slightly less effective than certain COX-2 inhibitors 3, 4.
In a randomized trial comparing rofecoxib, diclofenac, and meloxicam, meloxicam (15 mg daily) showed lower response rates compared to rofecoxib on days 3 and 8 (40% vs 84.2% patient global response, P=0.005) 3.
A 2020 meta-analysis found etoricoxib showed more favorable pain outcomes than meloxicam, though the difference was not statistically significant for all measures 4.
Practical Selection Criteria
Treatment selection should be driven by patient-specific factors rather than choosing one NSAID over another 2, 1:
Renal disease, heart failure, or cirrhosis: NSAIDs may be contraindicated; consider corticosteroids instead 1.
Gastrointestinal risk: COX-2 selective inhibitors probably cause fewer GI adverse events than non-selective NSAIDs like meloxicam 5.
Cost considerations: Generic NSAIDs including meloxicam are low-cost options compared to colchicine or IL-1 inhibitors 1.
Cardiovascular comorbidities: Assess cardiovascular risk factors before initiating any NSAID 6.
Dosing and Duration
Early initiation is more important than which specific NSAID is chosen - the most critical determinant of therapeutic success is how soon NSAID therapy begins 7.
Appropriate dosing and duration should be guided by flare severity 2.
Continue anti-inflammatory therapy until the flare resolves 2.
Common Pitfalls
Avoid assuming indomethacin is superior - despite being traditionally considered first-line, there is no evidence it is more efficacious than other NSAIDs 1.
Do not overlook contraindications - NSAIDs carry risks of dyspepsia, GI bleeding, and renal complications that must be weighed against benefits 1, 5.
Consider corticosteroids as potentially safer first-line therapy in patients without contraindications, as they are generally safer with fewer adverse effects than NSAIDs 1.